1. Introduction {#s0010}
===============

Anthelmintic resistance in nematode parasites of grazing animals is an expanding problem and is of major concern in many countries ([@bib0060; @bib0265; @bib0020; @bib0240]). As anthelmintics are generally the cornerstone of most parasite control programmes, the impact of parasites which are resistant to these drugs can be considerable ([@bib0020; @bib0245; @bib0180; @bib0235]). In order to retain the effectiveness of anthelmintics for as long as possible, it is essential that strategies are developed and implemented which can slow or prevent the development of resistance ([@bib0020; @bib0185]). With respect to nematode parasites of sheep, there has been extensive research over many years aiming to increase our understanding of the factors influencing the development of resistance, and its management once present ([@bib0010; @bib0115; @bib0100]). As a result, for sheep at least, there is an array of established approaches for managing resistance ([@bib0100]).

Historically, one of the main strategies promoted to slow the development of resistance was to alternate (rotate) the class of anthelmintic used on an approximately annual basis ([@bib0035; @bib0200; @bib0280; @bib0030]). This recommendation was based on the expectation that if there was a fitness cost associated with being resistant then rotating anthelmintics would allow the opportunity for reversion towards susceptibility to occur in the period when alternative drugs were used. Also, it was considered that by not exposing individual worms to more than one class of anthelmintic, selection for resistance to multiple actives was less likely to occur ([@bib0200]). The practice of rotating different anthelmintic classes annually was widely adopted in some countries ([@bib0070; @bib0280; @bib0075; @bib0220]) and is still promoted today in some countries and classes of animals ([@bib0170]). However, in the interim resistance has continued to develop and resistance to multiple anthelmintic classes is now well established on some farms ([@bib0255; @bib0265; @bib0080; @bib0250; @bib0175; @bib0045]).

An alternative approach to drug use was suggested by early modelling studies ([@bib0230; @bib0010]) which showed that simultaneously using multiple actives, with similar spectra of activity, had the potential to dramatically slow the development of resistance. Subsequently, commercial interests developed and marketted such combination anthelmintic products and these are now used extensively in some countries, but are still not available in others ([@bib0015; @bib0040]). Subsequent modelling and empirical studies have continued to support the use of combinations to slow the development of resistance ([@bib0085; @bib0090; @bib0120]). However, both modelling and empirical studies indicate that when the frequency of resistance alleles is already high in a population, combinations lose much of their ability to slow the further development of resistance ([@bib0120]). This has been used as an argument against the use of combinations ([@bib0030]) and a perception has developed that their use, once resistance to multiple anthelmintic classes has already established, will result in the further and rapid escalation of resistance to all of the different classes. This perception has created a dilemma for those farmers and their advisors who, prior to the release of new anthelmintic actives (monepantel ([@bib0055]) and derquantel ([@bib0125])) found themselves in a situation where no single active product would work effectively on their farm and the only products which could be used to maintain control were combinations.

Between 2010 and 2013, a four year extension programme was run to implement and evaluate parasite and resistance management programmes on commercial sheep and beef farms throughout New Zealand ([@bib0215]). One of the principle aims of this programme was to implement strategies which would maintain or improve on-farm productivity whilst preventing any further increase in the resistance status of parasites on the farms. Given that most of the sheep farms enrolled in this programme already had significant resistance to at least two anthelmintic classes, routine use of combination anthelmintics was inevitable. This situation, therefore, presented an opportunity to follow the progress of anthelmintic resistance on a number of farms under integrated resistance management programmes which included, along with other refugia and management practices, the almost exclusive use of combination anthelmintics.

2. Materials and methods {#s0015}
========================

2.1. The best practice parasite management programme {#s0020}
----------------------------------------------------

The Best Practice Parasite Management programme (BPPMP) was an industry-funded programme which aimed to develop and implement parasite and resistance management programmes on a diverse range of farms throughout the country and to evaluate their performance over time ([@bib0215]). Details of the programme will be published elsewhere, but briefly the intent was to design a parasite management programme specifically to fit the requirements of each farm and farmer, in order to maintain or improve production and profitability, whilst ensuring that the efficacy of anthelmintics did not decline from its initial level.

The programme involved an annual visit to the farm by the farm veterinarian, a parasitologist and an agricultural consultant. A whole-of-farm approach was taken such that at each visit a comprehensive review was undertaken of farm practices and events (e.g. purchase and sale of stock, livestock management, fertiliser applications, and crops grown) over the previous 12 month period along with a detailed review of the current animal health programme. Modifications to the plan were then discussed, informed by any monitoring data, and changes agreed upon for implementation in the following year along with a programme to monitor parasite levels (through regular faecal nematode egg counts (FEC) and coprocultures). Over the following 12 months the plan was implemented by the farmer with assistance from the veterinarians.

2.2. Resistance management strategies {#s0025}
-------------------------------------

The suite of parasite control and resistance management strategies implemented varied depending on the characteristics of each farm, so no two farms applied the same set of strategies in the same way. There were, however, some consistent underlying principles which can be grouped as:

1.use effective anthelmintic products i.e. on the basis of annual efficacy tests, select products which will achieve high efficacy against all worm species (at least 95%). Because all seven farms were known to have resistance to at least two anthelmintic classes, this required the use of combination products and/or new actives.2.avoid over-use of anthelmintics i.e. maintain a structured preventive programme of treatments to lambs ([@bib0260]) with all other treatments on the basis of demonstrated need (i.e. signs of illthrift or FEC) ([@bib0100]).3.do not administer anthelmintic treatments at intervals shorter than 28 days to allow for some limited contamination of pastures with susceptible genotypes after the pre-patent period of new infection.4.minimise or eliminate the use of anthelmintics with persistent activity ([@bib0100]).5.administer a single treatment, containing a new anthelmintic class, to lambs in late summer to remove resistant genotype worms which have accumulated over previous treatments ([@bib0105]).6.maximise the opportunities for retention of unselected genotypes (i.e. to maintain refugia). The principal method used to achieve this was to minimise the treatment of adult sheep and ensure that treated lambs and untreated ewes grazed over the same pastures as much as possible. Where this was not practical other approaches were used ([@bib0110; @bib0100]).7.maximise the use of integrated grazing (cattle, deer, sheep) and crops to minimise parasite challenge to susceptible stock, and adjust anthelmintic treatment schedules accordingly.8.ensure that anthelmintic treatments did not coincide with a shift to pastures likely to have low numbers of infective larvae unless other strategies were in place to ensure adequate refugia (e.g. treated lambs followed by untreated adult sheep) ([@bib0270]).9.effective quarantine procedures to prevent the introduction of resistant genotypes with stock transferred onto the farm ([@bib0100]).

Following each annual visit by the advisory team, throughout the course of the programme, each farmer was allocated a subjective scoring for their level of adoption of practices within each of the above categories ([Table 1](#t0010){ref-type="table"}).

2.3. Monitoring anthelmintic efficacy {#s0030}
-------------------------------------

An annual faecal egg count reduction test (FECRT) was undertaken on all farms to monitor anthelmintic efficacy over time. Where feasible this was continued after the programme finished, so that anthelmintic efficacy was monitored for five years on most farms.

Each year, a mob of at least 60 lambs was set aside before weaning, and these animals were monitored for FEC and remained untreated with anthelmintics until the mean count from 10 samples reached approximately 750 eggs per g faeces (epg). Where-ever possible the test was conducted on lambs which had never been treated previously with anthelmintic, thereby removing the possibility that previous treatments would bias the result by not completely removing all worm genotypes. The veterinarian was sent a kit containing everything needed to carry out the test including the anthelmintics, which ensured that all tests were conducted using the same anthelmintic products, which in most cases came from the same container. Faecal samples were couriered to a central laboratory for processing so that all processing was carried out by the same personnel.

Each FECRT comprised 4 treatment groups each of at least 12 animals. On day 0 all animals were weighed, sampled for FEC and then administered either; albendazole at 5.0 mg/kg live weight (Albendazole, Merial New Zealand Ltd), levamisole at 7.5 mg/kg live weight (Levicare Hi Mineral, Merial New Zealand Ltd), ivermectin at 0.2 mg/kg live weight (Ivomec Liquid for sheep & goats, Merial New Zealand Ltd) or were left as an untreated control. Seven to ten days after treatment a second faecal sample was collected from all animals.

Samples were kept cool and couriered over night to the laboratory. Faecal egg counts were performed using a modified McMaster method ([@bib0130]) where one egg seen equated to 50 epg. Faeces from the post-treatment samples was pooled by treatment group and cultured at 22 °C for 14 days before undergoing baermannisation to extract the third stage larvae (L3) ([@bib0050]). Individual L3 (N = 96) from each culture were identified to species using a multiplexed PCR technique with primers designed to target unique sequence motifs present in the second internal transcribed spacer region of the ribosomal DNA of each of the larval species ([@bib0025; @bib0275]). The proportion of each nematode species in the culture from the control samples was used to apportion FEC to species in the pre-test treated groups. Similarly, FEC in the post-treatment samples was apportioned to species based on the proportion of each species in the post-treatment samples ([@bib0160]). These numbers were then used to calculate the efficacy (reduction in FEC) of treatment for each species of nematode using the equation below ([@bib0190; @bib0265]). For the purpose of this study anthelmintic resistance was defined as a \<95% reduction in FEC ([@bib0155]). Ninety-five per cent confidence intervals around the efficacy were calculated using the formulae of [@bib0135].$$\begin{array}{l}
{1 - \left\{ \left\{ \frac{\left\{ {mean\, epg\, post\, treatment \ast \left( {{n\, treatment\, larvae}/100} \right)} \right\}}{\left\{ {\text{mean}\,\text{epg}\,\text{pre}\,\text{treatment} \ast \left( {{n\,\text{control}\,\text{larvae}}/100} \right)} \right\}} \right\} \right.} \\
{\left. {\quad \ast \,\left\{ \frac{mean\, epg\, pre\, treatment}{mean\, epg\, post\, treatment} \right\}} \right\} \ast 100} \\
\end{array}$$

2.4. Statistical analysis {#s0035}
-------------------------

Resistance was mostly commonly identified in *Teladorsagia circumcincta*, and this was the only species in which resistance to ivermectin was identified. Therefore, this was the only nematode species for which resistance to all three of the tested anthelmintics was found. Seven farms were identified as having resistance to two or more anthelmintics in this nematode species at the beginning of the BPPM programme, and as the aim was to examine any possible worsening of resistance over the course of the programme, analysis of the efficacy data was restricted to this species.

Separate analyses were conducted for each of the three actives. Linear regression, weighted by the apportioned FEC (so efficacy figures based on low egg counts had less influence than those based on higher numbers) was used. Only linear regression models were explored due to some farms not having data for all 5 years (thus non-linear models have not been considered). Since the slopes and intercepts associated with the linear regression model fitted for each of the seven farms may be different, the 'Random coefficient regression models' ([@bib0210]) were utilised. Modelling was undertaken using the *lmer* function of the package *lme4* of the R software ([@bib0205]).

3. Results {#s0040}
==========

Overall, all farmers made consistent efforts to adopt most of the resistance management practices worked out with their advisors ([Table 1](#t0010){ref-type="table"}). The majority of anthelmintic treatments were with combination products, the only exceptions being a strategic annual treatment with the new active monepantel on 5 farms and a single annual treatment with moxidectin for control of *Haemonchus contortus* on farm M. Although, the detail of how strategies were implemented invariably differed between farms the efforts made by the farmers resulted in scores of 3 (on a scale of 0--3) for most resistance management practices ([Table 1](#t0010){ref-type="table"}).

At the start of the BPPMP, three of the 10 sheep farms had *T. circumcincta* resistant to two classes of anthelmintic and four had populations resistant to all 3 classes. Several farms had serious resistance to all 3 actives. For example, Farm M had efficacies for albendazole, levamisole and ivermectin of 0%, 70% and 0%, respectively, whilst Farm K had efficacies of 40%, 88% and 10% for the same actives ([Table 2](#t0015){ref-type="table"}).

Across the 7 farms, the efficacy of albendazole against *T. circumcincta* averaged 66% in year one, ranging from 0 to 96%. At the end of the 5 years the average efficacy had increased to 90% and ranged from 71 to 100%. Although the regression had a positive slope of 3.8, this was not significant (p = 0.17) ([Fig. 1a](#f0015){ref-type="fig"}).

The efficacy of levamisole against *T. circumcincta* also averaged 66% in year one with a range of 27 to 91% across the 7 farms. By year 5 the average efficacy was 85% with a range of 56 to 98%. The slope of the linear regression was 5.4 which was significant with p = 0.04 ([Fig. 1b](#f0015){ref-type="fig"}).

The efficacy of ivermectin against *T. circumcincta* averaged 55% in year one with a range of 0 to 93%. By year 5 the average had increased to 86% and the range reduced to 67 to 100%. With a positive slope of 8.6 this increase in efficacy was also significant with p = 0.01 ([Fig. 1c](#f0015){ref-type="fig"}). Farm B was not included in the ivermectin analysis due to high efficacy with this active throughout the study resulting in no variance.

In the final FECRT, three farms were still classified as resistant to all three actives; one farm was resistant to two actives; two farms were resistant to one active and one farm had no resistance to the three actives. The efficacy of the actives on the three farms still showing triple resistance had increased, in some cases dramatically. For example, Farm M had final efficacies for albendazole, levamisole and ivermectin of 83%, 77% and 71%, respectively, whilst Farm K had efficacies of 96%, 94% and 95% for the same actives ([Table 2](#t0015){ref-type="table"}).

4. Discussion {#s0045}
=============

The purpose of this study was to monitor the efficacy (i.e. level of resistance) in *T. circumcincta* under best practice parasite management in order to ascertain whether the strategies implemented were able to prevent resistance from becoming any worse. On the seven farms which started the programme with resistance to at least two classes of anthelmintic, not only did resistance not get any worse, but overall there was a significant improvement in the effectiveness of both levamisole and ivermectin i.e. there was evidence for some reversion towards susceptibility. This result was unexpected for a number of reasons. Firstly, as resistance was already well advanced on all these farms, it seemed reasonable to expect that any initial fitness cost associated with resistant genotypes would have been eroded by re-association of resistance and fitness traits during the selection process ([@bib0065; @bib0150; @bib0145; @bib0195]). Secondly, all these farms routinely used combination anthelmintics throughout the BPPMP, and so there seemed little opportunity for any release from selection which would be an expected requirement for reversion to occur ([@bib0195]). Thirdly, on some farms the efficacy levels were so low at the start of the BPPMP that a further rapid decline in efficacy might have been expected under continued selection ([@bib0030]). Clearly this did not happen.

A recent modelling study may offer at least a partial explanation for these findings ([@bib0095]). This study compared the effect of using drugs in combination with an annual rotation, under different levels of fitness cost associated with resistant genotypes, and assumed that fitness costs were additive when worms carried multiple sets of resistance genes i.e. that worms carrying multiple sets of resistance genes were less fit than those resistant to just one drug. The results indicated that reversion was more likely to occur (i.e. at lower fitness costs) when drugs were used in combination than in rotation because the combination removed all resistant worm genotypes except those simultaneously carrying multiple sets of resistance genes, which were the least fit. Further, it was found that the size of the worm population in refugia was also important, with resistance being delayed more and reversion occurring at lower fitness costs when a larger proportion of the worm population was not exposed to treatment. There is evidence to support a fitness cost in being resistant, studies on *T. colubriformis* and *H. contortus* have shown reduced establishment in resistant isolates ([@bib0140; @bib0145]). [@bib0225] and [@bib0145] also found that the proportion of viable eggs being produced by resistant isolates of *H. contortus* was much less than that produced by susceptible isolates.

The BPPMP applied a number of resistance management strategies to every farm ([Table 1](#t0010){ref-type="table"}) and the set of strategies was invariably different, either in composition or in the manner in which they were applied. Therefore, it is not possible to determine which strategies contributed, or had the greatest impact, on the results reported here. Indeed, it is likely that the different mixtures of strategies implemented on different farms contributed to the variability in degree of reversion seen on different farms. However, given that along with the use of effective combination anthelmintics, substantial efforts were also made to avoid unnecessary treatments and ensure the maximum refugia consistent with production targets, it seems highly likely that the complex of strategies was effective rather than any individual approach. The results are, however, consistent with the hypothesis raised by [@bib0095] that reversion to susceptibility can occur when combination anthelmintics are used, especially when high levels of refugia are also maintained.

In Australia and New Zealand, farmers are often required to use combination anthelmintics just to maintain control, unless they can afford the additional cost of using products containing new actives ([@bib0165; @bib0100]). The results of this study offer some encouragement for these farmers and their long-term future in that the use of combination anthelmintics against worm populations which were already demonstrating well developed resistance to multiple actives did not result in any escalation towards total treatment failure. In fact, for all the farmers involved in this study, the efficacy of the double or triple combination anthelmintics which they were using actually increased over the duration of the BPPMP. Clearly, this would have increased their ability to maintain worm control and improved the long-term sustainability of their farming operation. On some farms this increase in efficacy was substantial e.g. Farm M, where efficacy increased from 0% for two drugs in year one to around 80% by the 5th year for all the drugs. It must, however, be emphasised that in this study a suite of changes were made to achieve this goal and that just switching to use of combination drenches, without addressing other issues such as the size of the selection pressure and maintaining refugia of susceptibility, may not produce the same result.

The key finding from this study is that when anthelmintics containing multiple actives were used against worm populations with varying levels of resistance to two or more of these actives, resistance did not get worse. What-is-more, evidence was found for significant reversion towards susceptibility. It must be noted, however, that combination anthelmintics were not used in isolation from other resistance management strategies, and so it cannot be assumed that combinations alone would have achieved this outcome. The results are consistent with the findings of a recent modelling study which indicated that reversion towards susceptibility is feasible when using anthelmintics in combination if individuals resistant to multiple actives are less fit than those resistant to only one ([@bib0095]). Work is currently underway to determine whether differences in fitness between isolates and genotypes might explain these results.
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![Efficacy of (a) albendazole, (b) levamisole and (c) ivermectin against *Teladorsagia circumcincta* as measured by faecal egg count reduction on 7 sheep farms over 5 years.](ijpddr98-fig-0001){#f0015}

###### 

The anthelmintics used, the annual number of treatments to lambs and the mean interval between these treatments, along with a qualitative scoring on the level of adoption by farmers of best practice parasite management practices, for each of the 7 farms in the study.

  -----------------------------------------------------------------------------------------------
  Factor                                         Farm                                      
  ---------------------------------------------- ------ ------ ------ ------ ------ ------ ------
  Actives used (use effective products)          AL\    ABL\   BL\    ABL\   ABL\   ABL\   ABL\
                                                 AD\    Mon    ABL\   Mon    Mox\   Mon    AD
                                                 ABL           Mon           Mon           

  Average annual number of treatments to lambs   9      7      10     7      8      7      7

  Average interval between treatments (days)     28     29     30     28     29     28     39

  Avoid over-use of anthelmintics                ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓     ✓✓✓    ✓✓✓

  No long acting treatments                      ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓     ✓      ✓✓✓

  Use a new active in summer                     ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓

  Maintain 'Refugia' of susceptibility           ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓     ✓✓✓    ✓✓

  Integrated grazing                             ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓      ✓✓     ✓✓✓

  No treat and shift                             ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓     ✓✓     ✓✓✓

  Effective quarantine                           ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓    ✓✓✓
  -----------------------------------------------------------------------------------------------

✓, low level of adoption; ✓✓, medium level of adoption; ✓✓✓, high level of adoption.

AL, Abamectin, levamisole; AD, Abamectin, derquantel; ABL, Abamectin, levamisole, oxfendazole/albendazole; Mon, Monepantel; BL, Albendazole, levamisole; Mox, Moxidectin.

###### 

Efficacy data for *Teladorsagia circumcincta* against each active tested (A -- Albendazole, B -- Levamisole and C -- Ivermectin) with 95% confidence intervals (CI) for the 7 farms over the 4 years of the project and the one follow up year. The faecal egg counts allocated to *T. circumcincta* based on the proportion of this species found in the control cultures and used as a covariant in the analysis are also given.

                      Year of test                                            
  ------------------- -------------- --------- ---------- --------- --------- -----
  \(A\) Albendazole                                                           
  Farm B              \% efficacy    51        86         92        NT        71
  95% CI              12--73         79--91    89--93     9--92               
  FEC                 175            1101      875        73                  
  Farm D              \% efficacy    96        98         100       100       100
  95% CI              95--97         97--99    97--100    96--100   98--100   
  FEC                 625            153       118        30        86        
  Farm H              \% efficacy    96        100        98        95        98
  95% CI              93--98         97--100   94--99     93--96    96--99    
  FEC                 21             114       25         35        72        
  Farm K              \% efficacy    40        NT         100       67        96
  95% CI              −30--72        95--100   55--77     94--98              
  FEC                 84             44        242        265                 
  Farm M              \% efficacy    −9        70         92        97        83
  95% CI              −55--24        53--81    69--98     94--99    59--92    
  FEC                 53             596       160        1007      75        
  Farm P              \% efficacy    87        53         73        53        NT
  95% CI              78--92         24--71    61--80     25--69              
  FEC                 88             48        30         23                  
  Farm W              \% efficacy    92        NT         97        56        91
  95% CI              91--93         85--99    31--73     68--97              
  FEC                 285            32        102        104                 
  \(B\) Levamisole                                                            
  Farm B              \% efficacy    27        92         98        NT        56
  95% CI              −1--48         85--95    97--99     17--79              
  FEC                 175            1101      875        73                  
  Farm D              \% efficacy    75        99         96        98        98
  95% CI              50--87         98--100   93--98     97--100   90--100   
  FEC                 625            153       118        30        86        
  Farm H              \% efficacy    91        98         100       98        94
  95% CI              64--98         85--100   93--100    75--100   78--98    
  FEC                 21             114       25         35        72        
  Farm K              \% efficacy    88        NT         100       95        94
  95% CI              80--93         96--100   84--99     84--98              
  FEC                 84             44        242        265                 
  Farm M              \% efficacy    70        99         98        100       77
  95% CI              8--90          93--100   76--100    99--100   50--88    
  FEC                 53             596       160        1007      75        
  Farm P              \% efficacy    36        94         96        89        NT
  95% CI              −19--66        47--99    90--98     66--96              
  FEC                 88             48        30         23                  
  Farm W              \% efficacy    78        NT         99        86        92
  95% CI              65--86         98--100   59--95     78--97              
  FEC                 285            32        102        104                 
  \(C\) Ivermectin                                                            
  Farm D              \% efficacy    93        98         100       100       100
  95% CI              79--97         95--99    98--100    96--100   97--100   
  FEC                 625            153       118        30        86        
  Farm H              \% efficacy    90        100        33        97        95
  95% CI              52--98         98--100   −131--75   91--99    76--99    
  FEC                 21             114       25         35        72        
  Farm K              \% efficacy    10        NT         79        54        95
  95% CI              −155--68       28--94    15--76     84--98              
  FEC                 84             44        242        265                 
  Farm M              \% efficacy    −128      64         66        97        71
  95% CI              −237--−55      45--77    50--77     93--98    53--80    
  FEC                 53             596       160        1007      75        
  Farm P              \% efficacy    82        72         100       90        NT
  95% CI              42--95         −95--96   96--100    74--96              
  FEC                 88             48        30         23                  
  Farm W              \% efficacy    58        NT         99        97        67
  95% CI              29--75         93--100   73--100    12--88              
  FEC                 285            32        102        104                 

NT, not tested.
